Age-related macular degeneration 2

Common Name(s)

Age-related macular degeneration 2

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Age-related macular degeneration 2" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Age-related macular degeneration 2" returned 25 free, full-text research articles on human participants. First 3 results:

Increase in peripheral blood mononuclear cell Toll-like receptor 2/3 expression and reactivity to their ligands in a cohort of patients with wet age-related macular degeneration.
 

Author(s): Yi Zhu, Liang Liang, Dan Qian, Hongsong Yu, Peizeng Yang, Bo Lei, Hui Peng

Journal:

 

To investigate Toll-like receptor (TLR) expression and reactivity in patients with the wet form age-related macular degeneration (AMD).

Last Updated: 15 Aug 2013

Go To URL

Last Updated: 11 Apr 2014

Go To URL
Serum levels of matrix metalloproteinase 2 and matrix metalloproteinase 9 elevated in polypoidal choroidal vasculopathy but not in age-related macular degeneration.
 

Author(s): Renpan Zeng, Feng Wen, Xiongze Zhang, Yu Su

Journal: Mol. Vis.. 2013 ;19():729-36.

 

Age-related macular degeneration (AMD) and polypoidal choroidal vasculopathy (PCV) are the leading causes of vision loss in the elderly Asian population. Previous studies have confirmed that abnormal extracellular matrix (ECM) metabolism plays an important role in the pathogenesis ...

Last Updated: 5 Apr 2013

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Age-related macular degeneration 2" returned 1 free, full-text review articles on human participants. First 3 results:

The association between complement component 2/complement factor B polymorphisms and age-related macular degeneration: a HuGE review and meta-analysis.
 

Author(s): Ammarin Thakkinstian, Mark McEvoy, Usha Chakravarthy, Subhabrata Chakrabarti, Gareth J McKay, Euijung Ryu, Giuliana Silvestri, Inderjeet Kaur, Peter Francis, Takeshi Iwata, Masakazu Akahori, Astrid Arning, Albert O Edwards, Johanna M Seddon, John Attia

Journal: Am. J. Epidemiol.. 2012 Sep;176(5):361-72.

 

The authors performed a systematic review of the association of complement component 2(C2)/complement factor B (CFB) gene polymorphisms with age-related macular degeneration (AMD). In total, data from 19 studies published between 2006 and 2011 were pooled for 4 polymorphisms: rs9332739 ...

Last Updated: 29 Aug 2012

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Safety and Tolerability of Ranibizumab in Mono/Bilateral w-AMD Patients in Eyes With BCVA<2/10 and/or 2nd Affected Eye
 

Status: Recruiting

Condition Summary: Wet Age Related Macular Degeneration

 

Last Updated: 28 May 2014

Go to URL
Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.
 

Status: Recruiting

Condition Summary: Neovascular Age-related Macular Degeneration

 

Last Updated: 26 Feb 2014

Go to URL